ମୋକ୍ସେଟୁମୋମାବ ପାସୁଡୋଟକ୍ସ

ମୋକ୍ସେଟୁମୋମାବ ପାସୁଡୋଟକ୍ସ
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	CD22
Clinical data
Trade names	Lumoxiti
Synonyms	Moxetumomab pasudotox-tdfk, CAT-8015
AHFS/Drugs.com	monograph
MedlinePlus	a618052
data	EU EMA: yes; US DailyMed: Moxetumomab_pasudotox;
Pregnancy; category	Contraindicated;
Routes of; administration	Intravenous
Legal status
Legal status	US: ℞-only ; EU: Rx-only ;
Chemical and physical data
Formula	C2804H4339N783O870S14
Molar mass	୬୩,୩୮୮.୦୧ g·mol−1
(verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Moxetumomab_pasudotox

ମୋକ୍ସେଟୁମୋମାବ ପାସୁଡୋଟକ୍ସ, ବିକ୍ରୟ ନାମ ଲୁମୋକ୍ସିଟି, ଏକ ଔଷଧ ଯାହା ହେୟାରି ସେଲ ଲିଉକେମିଆ (HCL) ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୪] ଯେତେବେଳେ ଅନ୍ୟ ଚିକିତ୍ସା କାମ କରେ ନାହିଁ ସେତେବେଳେ ଏହା ବ୍ୟବହୃତ ହୁଏ ।^[୩] ଏହା ଏକ ଶିରାରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଧୀରେ ଧୀରେ ଦିଆଯାଏ ।^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଫୁଲା, ଅଇ, ମୁଣ୍ଡବିନ୍ଧା, ଜ୍ୱର, ତରଳ ଝାଡ଼ା, ଯକୃତ ପ୍ରଦାହ, କମ୍ ପ୍ଲାଟେଲେଟ୍ ଏବଂ କମ୍ ଲିମ୍ଫୋସାଇଟ୍ ହୋଇପାରେ ।^[୪] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କ୍ୟାପିଲାରୀ ଲିକ୍ ସିଣ୍ଡ୍ରୋମ, ହେମୋଲାଇଟିକ ୟୁରେମିକ୍ ସିଣ୍ଡ୍ରୋମ (HUS), ବୃକ୍‌କ ସମସ୍ୟା ଏବଂ ଇଲେକ୍ଟ୍ରୋଲାଇଟ୍ ଅସ୍ୱାଭାବିକତା ହୋଇପାରେ | ^[୩] ଏହା ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ସାଇଟୋଟକ୍ସିନ ସଂଯୁକ୍ତ ସିଡି୨୨ ସହିତ ଅନୁବନ୍ଧିତ ହୋଇଥାଏ ।^[୪]

୨୦୧୮ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ମୋକ୍ସେଟୁମୋମାବ ପାସୁଡୋଟକ୍ସକୁ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୪] ୨୦୨୧ ମସିହାରେ ଏହା ୟୁରୋପ ଏବଂ ବ୍ରିଟେନରେ ଅନୁମୋଦିତ ହୋଇଥିବାବେଳେ ସେହି ବର୍ଷ ପରବର୍ତ୍ତୀ ସମୟରେ ଏହାକୁ ପ୍ରତ୍ୟାହାର କରି ନିଆଯାଇଥିଲା ।^[୨] ^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ପ୍ରତି ୧ ମିଗ୍ରା ଔଷଧର ମୂଲ୍ୟ ୨୦୨୧ ସୁଦ୍ଧା ପ୍ରାୟ ୨୨୦୦ ଡଲାର ଥିଲା ।^[୬]

ଆଧାର[ସମ୍ପାଦନା]

↑ "Moxetumomab pasudotox (Lumoxiti) Use During Pregnancy". Drugs.com. 22 October 2018. Archived from the original on 24 January 2021. Retrieved 20 April 2020.
↑ ^୨.୦ ^୨.୧ "Lumoxiti EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 2 May 2021. Retrieved 1 May 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Lumoxiti- moxetumomab pasudotox injection, powder, lyophilized, for solution IV solution stabilizer solution". DailyMed. 25 January 2019. Archived from the original on 21 April 2020. Retrieved 20 April 2020.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Moxetumomab Pasudotox-tdfk Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 17 November 2021.
↑ "Moxetumomab pasudotox". SPS - Specialist Pharmacy Service. 8 December 2018. Archived from the original on 17 November 2021. Retrieved 17 November 2021.
↑ "Lumoxiti Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 22 April 2021. Retrieved 17 November 2021.

[Drugs.com_pregnancy-1] "Moxetumomab pasudotox (Lumoxiti) Use During Pregnancy". Drugs.com. 22 October 2018. Archived from the original on 24 January 2021. Retrieved 20 April 2020.

[EPAR2021-2] ୨.୦ ^୨.୧ "Lumoxiti EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 2 May 2021. Retrieved 1 May 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[PI2021-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Lumoxiti- moxetumomab pasudotox injection, powder, lyophilized, for solution IV solution stabilizer solution". DailyMed. 25 January 2019. Archived from the original on 21 April 2020. Retrieved 20 April 2020.

[AHFS2021-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Moxetumomab Pasudotox-tdfk Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 17 November 2021.

[SP2021-5] "Moxetumomab pasudotox". SPS - Specialist Pharmacy Service. 8 December 2018. Archived from the original on 17 November 2021. Retrieved 17 November 2021.

[6] "Lumoxiti Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 22 April 2021. Retrieved 17 November 2021.

[୧]

[୩]

[୨]

[୪]

[୫]

[୬]